All samples had acquired at least one additional mutation in signaling pathway genes that are well known to be involved in AML, including Ptpn11, Kras, Nras, Kit, Cbl, and Nfkb2 (Figure 5E). This evidence concerns the gene NFKB2 and acute myeloid leukemia.